🫁 Supporting Respiratory Drug Discovery at Pharmidex
January 15, 2026

Pharmidex offers a broad range of pre-clinical respiratory disease models to support drug discovery and development across multiple pulmonary indications.

Our capabilities include validated models for asthma (acute, chronic and severe/exacerbation), cough, idiopathic pulmonary fibrosis (IPF), acute lung injury/ARDS, respiratory infections, COPD and allergic rhinitis.
These models incorporate clinically relevant triggers and well-established positive controls, enabling robust and translational assessment of novel therapeutics.

Our integrated respiratory platforms are designed to help accelerate informed decision-making from early research through to advanced pre-clinical development.

If you are developing new therapies for respiratory diseases, we would be pleased to discuss how Pharmidex can support your programme.

🌐
www.pharmidex.com

FROM DISCOVERY TO DISTRIBUTION
April 16, 2026
Pharmidex is pleased to announce that Martin Barrett , Head of Business Development, will be attending FROM DISCOVERY TO DISTRIBUTION – Making Pharmaceuticals 2026 on 21–22 April 2026 at the Coventry Building Society Arena, UK. Martin looks forward to meeting pharma innovators, formulation scientists, manufacturing leaders and strategic partners to discuss drug discovery, development, translational science, and end-to-end pharmaceutical solutions. If you’re attending, feel free to stop by for a chat and explore how Pharmidex can support your programmes from discovery through development.
April 15, 2026
Pharmidex will be attending Swiss Biotech Day 2026 on 4–5 May 2026 at the Congress Center Basel, Switzerland. We look forward to meeting founders, investors, biotech leaders and scientific partners to discuss drug discovery, translational development and strategic R&D opportunities. Feel free to catch us for a chat!
April 9, 2026
Pharmidex partners with Data Sciences International (DSI) to utilise industry-leading whole body plethysmography (WBP) systems, incorporating the patented Halcyon® pneumotach noise suppression technology. This enables the delivery of high-quality preclinical respiratory studies with enhanced clarity, sensitivity and confidence. By leveraging the robustness of DSI’s WBP platform alongside Pharmidex’s scientific expertise, we offer well-characterised models to assess: • Cough responses • Hypercapnic challenge responses • Functional respiratory changes across disease states such as asthma This integrated approach supports reliable and translatable assessment of airway function, disease progression and therapeutic efficacy, helping to de-risk programmes and drive better decision-making in preclinical development. Always keen to hear how others are advancing respiratory endpoints in their studies.
More Posts